Description

Secondary outcome measures including adverse events or quality of life indicators in the L. reuteri and agave inulin supplementation trial. Safety and tolerability data are presented alongside efficacy outcomes.

Figure 4

Chart

Source Paper

Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy and Chronic Constipation: A Double-Blind Randomized Placebo Controlled …

Nutrients (2020)

PMID: 32998471

DOI: 10.3390/nu12102971

Cite This Figure

![Figure 4: Secondary outcome measures including adverse events or quality of life indicators in the L. reuteri and agave inulin supplementation trial. Safety and tolerability data are presented alongside efficacy outcomes.]()

> Source: Andrea A García Contreras et al. "Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy." *Nutrients*, 2020. PMID: [32998471](https://pubmed.ncbi.nlm.nih.gov/32998471/)

<figure>
  <img src="" alt="Secondary outcome measures including adverse events or quality of life indicators in the L. reuteri and agave inulin supplementation trial. Safety and tolerability data are presented alongside efficacy outcomes." />
  <figcaption>Figure 4. Secondary outcome measures including adverse events or quality of life indicators in the L. reuteri and agave inulin supplementation trial. Safety and tolerability data are presented alongside efficacy outcomes.<br>  Source: Andrea A García Contreras et al. "Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32998471/">32998471</a></figcaption>
</figure>

Related Evidence

Inulin for Chronic Constipation

Grade B · 6 studies